|
Video: What is a Stock Split?
|
|
Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system disorders. Co. has a portfolio of product including its drug, NUPLAZID (pimavanserin), which has been approved by the U.S. Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. NUPLAZID is a selective serotonin inverse agonist/antagonist, targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. According to our ACAD split history records, Acadia Pharmaceuticals has had 0 splits. | |
|
Acadia Pharmaceuticals (ACAD) has 0 splits in our ACAD split history database.
Looking at the ACAD split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Acadia Pharmaceuticals shares, starting with a $10,000 purchase of ACAD, presented on a split-history-adjusted basis factoring in the complete ACAD split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/28/2014 |
|
End date: |
04/24/2024 |
|
Start price/share: |
$19.15 |
|
End price/share: |
$16.59 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-13.37% |
|
Average Annual Total Return: |
-1.43% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$8,658.94 |
|
Years: |
10.00 |
|
|
|
|
|